PDCD1 and head and neck squamous cell carcinoma: These findings suggest that the dual immunotherapy combination of relatlimab and PD-1 has the potential to become a strategy to overcome immunotherapy resistance, providing new ideas for the immunotherapy of HNSCC (84).